Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.62 |
| ▸ | REN | P00797 | 2/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890830 | 0.96 | REN (0.61) | BIRC2RENKLK5CTSKCTSS | |
| SCHEMBL29498132 | 0.96 | REN (0.61) | BIRC2RENKLK5CTSKCTSS | |
| SCHEMBL22962240 | 0.95 | BIRC2 (0.60) | BIRC2RENKLK5CTSKCTSS | |
| SCHEMBL22962429 | 0.92 | REN (0.61) | BIRC2RENKLK5CTSKCTSS | |
| SCHEMBL29651542 | 0.89 | REN (0.57) | BIRC2RENKLK5CTSKCTSS | |
| SCHEMBL12890828 | 0.88 | KLK5 (0.58) | BIRC2RENKLK5CTSKCTSS | |
| SCHEMBL30135036 | 0.88 | CTSS (0.68) | RENKLK5CTSKCTSSCTSL | |
| SCHEMBL20030598 | 0.88 | CTSS (0.68) | RENKLK5CTSKCTSSCTSL | |
| SCHEMBL17138017 | 0.88 | CTSS (0.68) | RENKLK5CTSKCTSSCTSL | |
| SCHEMBL17138015 | 0.88 | CTSS (0.68) | RENKLK5CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022149584-A1 | PEPTIDE | ＡＧＣ株式会社 | 2022-07-14 | — | — | WO | disclosed |
| US-20220119440-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | AGC Inc. (JP) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119440-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | VIP, RFC2, QRFPR | BIRC2 2523/4885REN 1502/4885KLK5 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.